Sort by
Refine Your Search
-
Postdoctoral Associate (PDA) position in Clinical High Risk for Psychosis Program The PRIME Psychosis Risk Clinic (https://www.prime.research.yale.edu) at Yale University School of Medicine is recruiting for a postdoctoral associate position starting July 1, 2025. PRIME is a research and...
-
invites applications for a postdoctoral position. The successful candidate will be driving cutting-edge research into the mechanisms and engineering of cell–cell fusion and cell signaling in human
-
The Ishizuka / Olino Lab at Yale Cancer Center seeks creative and driven scientists to lead projects within the Lab. The candidate should have a strong background in biology, with a strong interest
-
Title of the Position: Postdoctoral Research Associate Department and School: Yale Clinical Neurosciences Imaging Center, Department of Neurology, School of Medicine Anticipated Appointment Dates:7/1/25-6/30/26 (1-year appointment, with the possibility of renewal) Email/Website:...
-
) Email/Website: stefania.nicoli@yale.edu / nicolilab.com Introduction of the School/Department: The Nicoli Lab is seeking a highly motivated Postdoctoral Researcher with expertise in RNA biology to
-
POSTDOCTORAL POSITION, RAREDON LABORATORY, 2025-2027 T32 Training Fellowship Yale School of Medicine Department of Anesthesiology Vascular Biology & Therapeutics Program in Translational Biomedicine
-
biology and receptor pharmacology. We seek individuals with a strong background in structural biology of membrane proteins, either cryo-EM or x-ray crystallography. We are focused on gaining mechanistic
-
biology lab that is focused on utilizing genetic approaches to understand and exploit resistance mechanisms to DNA damage. Our research program has a particular interest in studying the interplay between
-
, Biomedical Engineering, Computer Science, and Data Science. The Yale and VA NORSE study is a multicenter initiative focusing on New-Onset Refractory Status Epilepticus (NORSE), including its subtype of FIRES
-
methods for measuring genome-wide methylation signatures in blood to identify early-stage cancers or early recurrences after therapy. In addition, this platform technology is generating rich whole